|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.31 USD | +2.31% |
|
+0.57% | +41.22% |
| Apr. 15 | CorMedix's DefenCath Now Commercially Available For US Inpatient Use | MT |
| Apr. 15 | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) | CI |
Nov 15 (Reuters) - The U.S. Food and Drug Administration (FDA) on Wednesday approved CorMedix's antimicrobial drug that aims to reduce catheter-related bloodstream infections (CRBSIs) in patients with kidney disease, the regulator said. (Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)
| 1st Jan change | Capi. | |
|---|---|---|
| +41.22% | 292M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
CORMEDIX INC. 
